The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
In those on insulin, routinely checking blood sugar levels (such as through a continuous glucose monitor) is advised; however, this may not be needed in those who are not on insulin therapy. Bariatric surgery often improves diabetes in those who are obese. Rates of type 2 diabetes have increased markedly since 1960 in parallel with obesity. As of 2015, there were approximately 392 million people diagnosed with the disease compared to around 30 million in 1985. Typically, it begins in middle or older age, although rates of type 2 diabetes are increasing in young people. Type 2 diabetes is associated with a ten-year-shorter life expectancy. Diabetes was one of the first diseases ever described, dating back to an Egyptian manuscript from c. 1500 BCE. Two types of diabetes were identified in 400–500 CE, one type associated with youth (now identified as type 1) and the other associated with being overweight (now identified as type 2). The importance of insulin in the disease was determined in the 1920s.
The spine ends at the caudal peduncle, the base of the caudal fin, distinguishing this group from those in which the spine extends into the upper lobe of the caudal fin, such as most fish from the Paleozoic (541 to 252 million years ago). The neural arches are elongated to form uroneurals which provide support for this upper lobe. Teleosts tend to be quicker and more flexible than more basal bony fishes. Their skeletal structure has evolved towards greater lightness. While teleost bones are well calcified, they are constructed from a scaffolding of struts, rather than the dense cancellous bones of holostean fish. In addition, the lower jaw of the teleost is reduced to just three bones; the dentary, the angular bone and the articular bone. The genital and urinary tracts end behind the anus in the genital papilla; this is observed to sex teleosts.
== Distribution == The chain catshark is found in the Northwest Atlantic, Gulf of Mexico and Caribbean, ranging from George's Bank in Massachusetts, to Nicaragua and Barbados. In the Mid-Atlantic Bight, the chain catshark is found along the outer continental shelf and upper slope. The shark occupies depths of 36 to 750 meters (118–2,461 ft); in the northern part of its range it is mainly found between 36 and 230 meters (118–755 ft) and in the southern areas generally deeper than 460 meters (1,510 ft). Due to the shark's depth distribution, it has been suggested that the shark does not perform large-scale migrations. Temperature is thought to limit the shark's distribution in northern areas, particularly during the winter. Although bands of warm water at the edge of the shelf have been observed, the temperature varies seasonally, thus limiting this non-migratory species. In general, the chain catshark is found in waters with a temperature between 8.5 °C (47 °F) and 14 °C (57 °F).
S-adenosyl-L-homocysteine + [myelin basic protein]-Nomega-methyl-arginine Thus, the two substrates of this enzyme are S-adenosyl methionine and myelin basic protein-arginine, whereas its two products are S-adenosylhomocysteine and myelin basic protein-Nomega-methyl-arginine. This enzyme belongs to the family of transferases, specifically those transferring one-carbon group methyltransferases. The systematic name of this enzyme class is S-adenosyl-L-methionine:[myelin-basic-protein]-arginine Nomega-methyltransferase. Other names in common use include myelin basic protein methylase I, protein methylase I, S-adenosyl-L-methionine:[myelin-basic-protein]-arginine, and omega-N-methyltransferase.
electron configuration The distribution of the electrons of an atom or molecule within atomic or molecular orbitals. An extensive system of notation is used to concisely and uniquely display information about the electron configuration of each atomic species. Knowledge of the specific arrangements of electrons in different atoms is useful for understanding chemical bonds and the organization of the periodic table of the elements.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}K_{M}^{\prime }\ &{\stackrel {\mathrm {def} }{=}}\ {\frac {k_{3}}{k_{2}+k_{3}}}K_{M}={\frac {k_{3}}{k_{2}+k_{3}}}\cdot {\frac {k_{2}+k_{-1}}{k_{1}}}\\k_{cat}\ &{\stackrel {\mathrm {def} }{=}}\ {\dfrac {k_{3}k_{2}}{k_{2}+k_{3}}}\end{aligned}}}
After the internal structure of the atom was probed, amateur Dutch physicist Antonius van den Broek proposed in 1913 that the nuclear charge determined the placement of elements in the periodic table. The New Zealand physicist Ernest Rutherford coined the word "atomic number" for this nuclear charge. In van den Broek's published article he illustrated the first electronic periodic table showing the elements arranged according to the number of their electrons. Rutherford confirmed in his 1914 paper that Bohr had accepted the view of van den Broek. The same year, English physicist Henry Moseley using X-ray spectroscopy confirmed van den Broek's proposal experimentally. Moseley determined the value of the nuclear charge of each element from aluminium to gold and showed that Mendeleev's ordering actually places the elements in sequential order by nuclear charge. Nuclear charge is identical to proton count and determines the value of the atomic number (Z) of each element. Using atomic number gives a definitive, integer-based sequence for the elements. Moseley's research immediately resolved discrepancies between atomic weight and chemical properties; these were cases such as tellurium and iodine, where atomic number increases but atomic weight decreases. Although Moseley was soon killed in World War I, the Swedish physicist Manne Siegbahn continued his work up to uranium, and established that it was the element with the highest atomic number then known (92).
According to a study on well-being by Richards, Campania, and Muse-Burke, "mindfulness is considered to be a purposeful state, it may be that those who practice it belief in its importance and value being mindful, so that valuing of self-care activities may influence the intentional component of mindfulness." Akin to surgery, sometimes the body must be further damaged, before it can properly heal Mental health is conventionally defined as a hybrid of the absence of a mental disorder and the presence of well-being. Focus is increasing on preventing mental disorders. Prevention is beginning to appear in mental health strategies, including the 2004 WHO report "Prevention of Mental Disorders", the 2008 EU "Pact for Mental Health" and the 2011 US National Prevention Strategy. Some commentators have argued that a pragmatic and practical approach to mental disorder prevention at work would be to treat it the same way as physical injury prevention. Prevention of a disorder at a young age may significantly decrease the chances that a child will have a disorder later in life, and shall be the most efficient and effective measure from a public health perspective. Prevention may require the regular consultation of a physician for at least twice a year to detect any signs that reveal any mental health concerns. Additionally, social media is becoming a resource for prevention. In 2004, the Mental Health Services Act began to fund marketing initiatives to educate the public on mental health.
Eukaryotic cells were created some 2.2 billion years ago in a process called eukaryogenesis. This is widely agreed to have involved symbiogenesis, in which an archaean and a bacterium came together to create the first eukaryotic common ancestor. It evolved into a population of single-celled organisms that included the last eukaryotic common ancestor, gaining capabilities along the way. This cell had a new level of complexity, with a nucleus and facultatively aerobic mitochondria. It featured at least one centriole and cilium, sex (meiosis and syngamy), peroxisomes, and a dormant cyst with a cell wall of chitin and/or cellulose. The last eukaryotic common ancestor gave rise to the eukaryotes' crown group, containing the ancestors of animals, fungi, plants, and a diverse range of single-celled organisms. The green plants were created around 1.6 billion years ago with a second episode of symbiogenesis that added chloroplasts, derived from cyanobacteria.
Sources: en.wikipedia.org
Unlike the other Warsaw Pact leaders, Ceaușescu had not been slavishly pro-Soviet but rather had pursued an "independent" foreign policy; Romanian forces did not join their Warsaw Pact allies in putting an end to the Prague Spring—an invasion Ceaușescu openly denounced—while Romanian athletes competed at the Soviet-boycotted 1984 Summer Olympics in Los Angeles (receiving a standing ovation at the opening ceremonies and proceeding to win 53 medals, trailing only the United States and West Germany in the overall count). Conversely, while Soviet Communist Party General Secretary Mikhail Gorbachev spoke of reform, Ceaușescu maintained a hard political line and cult of personality. The austerity programme started in 1981 and the widespread poverty it introduced made the Communist regime very unpopular. The austerity programmes were met with little resistance among Romanians and there were only a few strikes and labour disputes, of which the Jiu Valley miners' strike of 1977 and the Brașov Rebellion of November 1987 at the truck manufacturer Steagul Roșu were the most notable. In March 1989, several leading activists of the PCR criticised Ceaușescu's economic policies in a letter, but shortly thereafter he achieved a significant political victory: Romania paid off its external debt of about US$11,000,000,000 several months before the time that even the Romanian dictator expected. However, in the months following the austerity programme, shortages of goods remained the same as before.
Distribution of products takes place through a marketing channel, also known as a distribution channel. A marketing channel is the people, organizations, and activities necessary to transfer the ownership of goods from the point of production to the point of consumption. It is the way products get to the end-user, the consumer. This is mostly accomplished through merchant retailers or wholesalers or, in the international context, by importers. In certain specialist markets, agents or brokers may become involved in the marketing channel: for example in the insurance sector, the European Union has noted that "insurance and reinsurance intermediaries play a central role in the distribution of insurance and reinsurance products" . The EU introduced the Insurance Distribution Directive in 2016 to enhance a level of harmonisation in this market across EU member states. Typical intermediaries involved in distribution include:
=== Secretion of Interleukin-10 === Genetically engineered L. lactis can secrete the cytokine interleukin-10 (IL-10) for the treatment of inflammatory bowel diseases (IBD), since IL-10 has a central role in downregulating inflammatory cascades and matrix metalloproteinases. A study by Lothar Steidler and Wolfgang Hans shows that in situ synthesis of IL-10 by genetically engineered L. lactis requires much lower doses than systemic treatments like antibodies to tumor necrosis factor (TNF) or recombinant IL-10. The authors propose two possible routes by which IL-10 can reach its therapeutic target. Genetically engineered L. lactis may produce murine IL-10 in the lumen, and the protein may diffuse to responsive cells in the epithelium or the lamina propria. Another route involves L. lactis being taken up by M cells because of its bacterial size and shape, and the major part of the effect may be due to recombinant IL-10 production in situ in intestinal lymphoid tissue. Both routes may involve paracellular transport mechanisms that are enhanced in inflammation. After transport, IL-10 may directly downregulate inflammation. In principle, this method may be useful for intestinal delivery of other protein therapeutics that are unstable or difficult to produce in large quantities and an alternative to the systemic treatment of IBD.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.